Cerebrospinal Fluid Microglial Markers in Alzheimer's Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility
(2011) In NeuroMolecular Medicine 13(2). p.151-159- Abstract
- Activated microglial cells, which are the resident macrophages of the central nervous system, surround amyloid beta-plaques in Alzheimer's disease (AD) brains. Inflammation including microglial activation may contribute in AD pathogenesis, and biomarkers for this process may thus be of value to study AD pathogenesis and might facilitate development of therapies targeting these cells. We therefore examined cerebrospinal fluid (CSF) biomarkers in patients with AD, other dementias, mild cognitive impairment and in healthy controls. Samples were analyzed for markers with known association to macrophage activity, including chitotriosidase, YKL-40 (CHI3L1, HC gp-39) and chemokine CC motif ligand 2 (CCL2, MCP1). Patients with AD had higher... (More)
- Activated microglial cells, which are the resident macrophages of the central nervous system, surround amyloid beta-plaques in Alzheimer's disease (AD) brains. Inflammation including microglial activation may contribute in AD pathogenesis, and biomarkers for this process may thus be of value to study AD pathogenesis and might facilitate development of therapies targeting these cells. We therefore examined cerebrospinal fluid (CSF) biomarkers in patients with AD, other dementias, mild cognitive impairment and in healthy controls. Samples were analyzed for markers with known association to macrophage activity, including chitotriosidase, YKL-40 (CHI3L1, HC gp-39) and chemokine CC motif ligand 2 (CCL2, MCP1). Patients with AD had higher chitotriosidase activity than controls and patients with stable mild cognitive impairment, consistent with the presence of activated microglial cells in AD brains, but with large overlaps between groups. CCL2 and YKL-40 concentrations did not differ among groups. Microglial markers are unlikely to be useful for AD diagnosis, but might be useful for identification of distinct subgroups of patients, and for the development and implementation of drugs targeting microglial pathology. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1985256
- author
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, Cerebrospinal fluid, Biomarker, Microglia, Cytokine, Chitotriosidase, YKL-40, CCL2
- in
- NeuroMolecular Medicine
- volume
- 13
- issue
- 2
- pages
- 151 - 159
- publisher
- Humana Press
- external identifiers
-
- wos:000291258000005
- scopus:80051547200
- ISSN
- 1535-1084
- DOI
- 10.1007/s12017-011-8147-9
- project
- Endocrine and diagnostic aspects of cognitive impairment
- language
- English
- LU publication?
- yes
- id
- 6599af1d-932d-49f5-b5e3-7a12cc1b911f (old id 1985256)
- date added to LUP
- 2016-04-01 11:08:09
- date last changed
- 2022-03-27 22:39:42
@article{6599af1d-932d-49f5-b5e3-7a12cc1b911f, abstract = {{Activated microglial cells, which are the resident macrophages of the central nervous system, surround amyloid beta-plaques in Alzheimer's disease (AD) brains. Inflammation including microglial activation may contribute in AD pathogenesis, and biomarkers for this process may thus be of value to study AD pathogenesis and might facilitate development of therapies targeting these cells. We therefore examined cerebrospinal fluid (CSF) biomarkers in patients with AD, other dementias, mild cognitive impairment and in healthy controls. Samples were analyzed for markers with known association to macrophage activity, including chitotriosidase, YKL-40 (CHI3L1, HC gp-39) and chemokine CC motif ligand 2 (CCL2, MCP1). Patients with AD had higher chitotriosidase activity than controls and patients with stable mild cognitive impairment, consistent with the presence of activated microglial cells in AD brains, but with large overlaps between groups. CCL2 and YKL-40 concentrations did not differ among groups. Microglial markers are unlikely to be useful for AD diagnosis, but might be useful for identification of distinct subgroups of patients, and for the development and implementation of drugs targeting microglial pathology.}}, author = {{Mattsson, Niklas and Tabatabaei, Shahrzad and Johansson, Per and Hansson, Oskar and Andreasson, Ulf and Mansson, Jan-Eric and Johansson, Jan-Ove and Olsson, Bob and Wallin, Anders and Svensson, Johan and Blennow, Kaj and Zetterberg, Henrik}}, issn = {{1535-1084}}, keywords = {{Alzheimer's disease; Cerebrospinal fluid; Biomarker; Microglia; Cytokine; Chitotriosidase; YKL-40; CCL2}}, language = {{eng}}, number = {{2}}, pages = {{151--159}}, publisher = {{Humana Press}}, series = {{NeuroMolecular Medicine}}, title = {{Cerebrospinal Fluid Microglial Markers in Alzheimer's Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility}}, url = {{http://dx.doi.org/10.1007/s12017-011-8147-9}}, doi = {{10.1007/s12017-011-8147-9}}, volume = {{13}}, year = {{2011}}, }